About 30% of acute myeloid leukemia patients have developed a mutation in the FLT3 gene. Up until recently, this specific mutation usually resulted in poor treatment outcomes. Today, we have several drugs designed to directly target this mutation and even more progress is occurring with newer drugs and various treatment combinations in clinical trials.
Dr. Kasner, an AML expert from the Sidney Kimmel Cancer Center at Thomas Jefferson University, will summarize key developments and clinical trials currently underway for FLT3 positive AML. If you have a FLT3 mutation, this radio show episode is definitely for you.
Katie joined the HealthTree Foundation as the Community Director for AML in 2021. She is a registered dietitian who previously worked at the VA hospital in Dallas, Texas where she coached veterans with blood cancer on how to use nutrition to improve their treatment outcomes and minimize cancer-related side effects. Katie is passionate about health education and patient empowerment. In her spare time, she loves to experiment with new recipes in the kitchen, spend time running outdoors and travel to new places.
Associate Professor of Medical Oncology in the Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation Division, Section Leader of the Leukemia Program in the Department of Medical Oncology and Co-Medical Director at the Clinical Trials Office, Sidney Kimmel Cancer Center at Thomas Jefferson University
Thank you for your interest in the event. If you have any question, we would love to help! Just fill out the form below and we will get back to you as quickly as possible.